| RGS8 — Regulator of G Protein Signaling 8 | |
|---|---|
| Symbol | RGS8 |
| Full Name | Regulator of G Protein Signaling 8 |
| Chromosome | 1q23.3 |
| NCBI Gene | 8317 |
| OMIM | 607231 |
| Ensembl | ENSG00000128564 |
| UniProt | P57774 |
| Diseases | [Epilepsy](/diseases/epilepsy), [Intellectual Disability](/diseases/intellectual-disability), [Parkinson's Disease](/diseases/parkinsons-disease), [Psychiatric Disorders](/diseases/psychiatric-disorders) |
| Expression | [Hippocampus](/brain-regions/hippocampus), Cerebral [cortex](/brain-regions/cortex), Cerebellum, Striatum |
RGS8 (Regulator of G Protein Signaling 8) is a brain-specific member of the RGS protein family with critical roles in modulating G protein-coupled receptor (GPCR) signaling in the central nervous system. RGS8 is predominantly expressed in neuronal populations involved in learning, memory, and motor control.
RGS8 encodes a 210-amino acid protein with a conserved RGS domain that functions as a GTPase-activating protein (GAP) primarily for Gαo and Gαi subunits. RGS8 exhibits neuronal specificity with high expression in the hippocampus, cerebral cortex, and cerebellum. The protein plays essential roles in regulating synaptic transmission and neuronal signaling.
RGS8 terminates GPCR signaling in neurons by accelerating GTP hydrolysis on Gαo and Gαi subunits. These G proteins mediate signaling from numerous neuronal receptors including dopamine receptors (particularly D2R), muscarinic acetylcholine receptors (M1/M4), serotonin receptors (5-HT1A/5-HT2), and opioid receptors (μ, δ, κ). RGS8 thereby modulates the duration and intensity of neurotransmitter signaling.
RGS8 is localized to both presynaptic terminals and postsynaptic compartments. At presynaptic sites, RGS8 regulates neurotransmitter release by controlling GPCR signaling that modulates calcium influx and vesicle release. Postsynaptically, RGS8 modulates receptor desensitization and downstream signaling cascades.
The hippocampus-enriched expression of RGS8 suggests roles in learning and memory processes. RGS8 modulates acetylcholine and dopamine signaling in hippocampal neurons, both neurotransmitter systems critical for memory formation and consolidation.
RGS8 dysregulation has been implicated in epilepsy pathogenesis. Altered RGS8 expression affects neuronal excitability and seizure threshold through modulation of GPCR signaling pathways that control neuronal firing.
RGS8 mutations have been associated with intellectual disability phenotypes. Given RGS8's role in synaptic plasticity and neuronal signaling, disruptions may impair cognitive development and function.
RGS8 modulates dopaminergic signaling in the striatum, making it relevant to Parkinson's disease pathogenesis. RGS8 interactions with D2 dopamine receptors may influence basal ganglia function and motor control.
RGS8's modulation of monoamine receptor signaling (dopamine, serotonin) links it to psychiatric conditions including schizophrenia, depression, and bipolar disorder.
RGS8 exhibits highly restricted expression, predominantly in the brain. Highest expression is found in the hippocampal formation (CA regions, dentate gyrus), cerebral cortex (layer 5 pyramidal neurons), cerebellar Purkinje cells, and striatum (medium spiny neurons). Lower expression is detected in thalamus and hypothalamus.
RGS8 represents a therapeutic target for: